{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acquired+Bleeding+Disorder&page=2",
    "query": {
      "condition": "Acquired Bleeding Disorder",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acquired+Bleeding+Disorder&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:50:18.151Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06096116",
      "title": "Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Antithrombin Deficiency"
      ],
      "interventions": [
        {
          "name": "Human plasma derived antithrombin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-08-21",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 9,
      "location_summary": "Stanford, California • Miami, Florida • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06096116"
    },
    {
      "nct_id": "NCT03700723",
      "title": "Comparison of the Efficacy & Safety of Resusix With FP24 in Patients With Acquired Coagulopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coagulopathy"
      ],
      "interventions": [
        {
          "name": "Resusix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FP24 (Frozen Plasma)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Entegrion, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-12-14",
      "completion_date": "2020-04-15",
      "has_results": false,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • St Louis, Missouri • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03700723"
    },
    {
      "nct_id": "NCT01151423",
      "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151423"
    },
    {
      "nct_id": "NCT01554514",
      "title": "Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-08",
      "completion_date": "2020-02-14",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01554514"
    },
    {
      "nct_id": "NCT00341705",
      "title": "The Second Multicenter Hemophilia Cohort Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Liver Decompensation",
        "Hepatocellular Carcinoma",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 2565,
      "start_date": "2001-04-27",
      "completion_date": "2013-04-02",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 39,
      "location_summary": "Tucson, Arizona • Davis, California • Orange, California + 31 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Davis",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00341705"
    },
    {
      "nct_id": "NCT03513328",
      "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Failure Syndrome",
        "Thalassemia",
        "Sickle Cell Disease",
        "Diamond Blackfan Anemia",
        "Acquired Neutropenia in Newborn",
        "Acquired Anemia Hemolytic",
        "Acquired Thrombocytopenia",
        "Hemophagocytic Lymphohistiocytoses",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "Common Variable Immunodeficiency",
        "X-linked Lymphoproliferative Disease",
        "Severe Combined Immunodeficiency",
        "Hurler Syndrome",
        "Mannosidosis",
        "Adrenoleukodystrophy"
      ],
      "interventions": [
        {
          "name": "Thiotepa--single daily dose",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa--escalated dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Months to 39 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-06-15",
      "completion_date": "2023-02-19",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513328"
    },
    {
      "nct_id": "NCT00001104",
      "title": "A Study of Zidovudine in HIV-Infected Patients Who Have Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 538,
      "start_date": null,
      "completion_date": "1990-02",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • San Diego, California • Stanford, California + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001104"
    },
    {
      "nct_id": "NCT01178294",
      "title": "Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acquired Hemophilia A"
      ],
      "interventions": [
        {
          "name": "OBI-1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2010-11-10",
      "completion_date": "2013-10-09",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 8,
      "location_summary": "Indianapolis, Indiana • New Orleans, Louisiana • Bethesda, Maryland + 4 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178294"
    },
    {
      "nct_id": "NCT07281313",
      "title": "Aphasia Physical EXercise Study: Randomized Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Aphasia, Acquired",
        "Aphasia",
        "Aphasia, Fluent",
        "Aphasia, Non-fluent",
        "Aphasia Following Cerebral Infarction",
        "Aphasia Following Nontraumatic Intracerebral Hemorrhage"
      ],
      "interventions": [
        {
          "name": "High-intensity physical exercise",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Low-intensity physical exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Berkeley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 120,
      "start_date": "2025-12-01",
      "completion_date": "2030-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 4,
      "location_summary": "Berkeley, California • Hayward, California • San Francisco, California",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Hayward",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07281313"
    },
    {
      "nct_id": "NCT00127283",
      "title": "Recombinant Factor VIIa in Acute Intracerebral Haemorrhage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Intracerebral Haemorrhage"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 829,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-05-22T07:50:18.151Z",
      "location_count": 77,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00127283"
    }
  ]
}